CARDIZEM LA Drug Patent Profile

Which patents cover Cardizem La, and what generic alternatives are available?

Cardizem La is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in CARDIZEM LA is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cardizem La

A generic version of CARDIZEM LA was approved as diltiazem hydrochloride by TEVA on May 31^st, 1995.

Summary for CARDIZEM LA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CARDIZEM LA

Paragraph IV (Patent) Challenges for CARDIZEM LA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CARDIZEM LA	Extended-release Tablets	diltiazem hydrochloride	120 mg, 180 mg, 240 mg, 300 mg and 360 mg	021392	1	2005-08-30
CARDIZEM LA	Extended-release Tablets	diltiazem hydrochloride	420 mg	021392	1	2005-04-25

US Patents and Regulatory Information for CARDIZEM LA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-001	Feb 6, 2003	AB	RX	Yes	No
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-004	Feb 6, 2003	AB	RX	Yes	No
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-002	Feb 6, 2003	AB	RX	Yes	No
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-003	Feb 6, 2003	AB	RX	Yes	No
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-006	Feb 6, 2003	AB	RX	Yes	Yes
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-005	Feb 6, 2003	AB	RX	Yes	No

International Patents for CARDIZEM LA

See the table below for patents covering CARDIZEM LA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	6566700
Japan	3725474
Austria	430561
European Patent Office	1131057	BILLES DE CIRE DE REMBOURRAGE POUR LA FABRICATION D'ARTICLES DE FORME SOLIDE (CUSHIONING WAX BEADS FOR MAKING SOLID SHAPED ARTICLES)
Canada	2348953	BILLES DE CIRE DE REMBOURRAGE POUR LA FABRICATION D'ARTICLESDE FORME SOLIDE (CUSHIONING WAX BEADS FOR MAKING SOLID SHAPED ARTICLES)
Japan	2003509454

Investment Scenario, Market Dynamics, and Financial Trajectory for CARDIZEM LA (DilTIAZEM Extended-Release)

Last updated: February 3, 2026

Executive Summary

CARDIZEM LA (brand name for DilTIAZEM) is a long-acting formulation of the calcium channel blocker used primarily for hypertension and angina management. Its patent expiration, competitive landscape, and evolving market dynamics are critical for investors and stakeholders. This report provides a comprehensive analysis of the current market environment, financial projections, competitive positioning, and strategic considerations. It emphasizes that CARDIZEM LA operates in a highly competitive, regulatory-sensitive setting with expanding indications and emerging alternatives, influencing its long-term investment viability.

---

1. Product Overview and Historical Financial Performance

Attribute	Details
Active Ingredient	Diltiazem hydrochloride (extended-release)
Therapeutic Class	Calcium channel blocker
Indications	Hypertension, Angina pectoris
Market Origin	Initiated in the 1980s, launched in the US in mid-1980s by Pfizer (Cardizem CD/LA)
Formulation	Extended-release capsule/tablet (24-hr dosing)
Patents & Exclusivity	Patents expired in key markets (e.g., US patent expired in 2014), resulting in generic entry

Historical Financials (Pre-Patent Expiry, 2000-2014)

Year	Sales (USD Millions)	Market Share	Notes
2000	650	Leading calcium channel blocker	High prescription rates, patent protection ongoing
2005	700	Market stability	Growing awareness of long-acting formulations
2010	800	Dominant position	Patent expiry impending, generic threats emerging
2014	2,200	Patent expired	Sharp decline in branded sales; generics gained above 80% market share

Post-2014, sales declined sharply as generics penetrated the market, with some stabilization due to formulary restrictions and brand loyalty from initiated long-term treatments.

---

2. Market Dynamics

2.1. Competitive Landscape

Competitors	Key Attributes	Market Share (2022)	Notes
Generic Diltiazem ER	Price advantage, comparable efficacy	~85%	Market penetration post-patent expiry
Brand-Name Variants	Brand recognition, reputation	~15%	Limited to niche indications or formulary preferences
Alternative Agents	Other CCBs (amlodipine, verapamil), ACE inhibitors	Variable	Competitive substitutes

2.2. Regulatory and Patent Environment

• Patent expiration accelerated generic entry.
• No recent patents on extended-release formulations.
• Certain market regions have introduced regulatory pathways favoring biosimilars or generics.

2.3. Prescriber and Patient Trends

• Increased adoption of fixed-dose combination therapies.
• Shift to newer, longer-acting agents with improved cardiovascular outcomes.
• Growing emphasis on personalized medicine affects prescribing patterns.

2.4. Market Size & Forecasts

Geography	2022 Market Value (USD Billion)	CAGR (2022-2027)	Drivers
US	1.0	3.5%	Hypertension prevalence, aging population
Europe	0.6	3.0%	Similar demographic trends
Asia-Pacific	0.4	6.0%	Rising healthcare access, chronic disease burden

Total global calcium channel blocker market estimated at USD 4.2 Billion in 2022.

2.5. Impact of Emerging Therapies

• Introduction of novel agents like angiotensin receptor-neprilysin inhibitors (ARNIs), SGLT2 inhibitors, and direct vasodilators.
• These drugs are gradually shifting some indications away from traditional CCBs.

---

3. Financial Trajectory and Investment Outlook

3.1. Revenue Projections

Scenario	2023	2025	2030	Assumptions
Conservative	USD 50M	USD 45M	USD 40M	Sustained generic competition, minor formulary success
Moderate Growth	USD 75M	USD 80M	USD 85M	Some niche markets, formulary wins, new indications
Optimistic	USD 100M	USD 120M	USD 150M	Strategic repositioning, niche therapy adoption, brand differentiation

Note: These projections assume limited patent protection and increasing commoditization unless new formulations or indications are developed.

3.2. Cost Considerations

Expenses	Details
R&D	Minimal, mainly lifecycle management
Manufacturing	Cost reduction driven by generics and economies of scale
Marketing & Promotion	Limited for generics; higher for niche branding campaigns
Regulatory Compliance	Ongoing, especially for new formulations or indications

3.3. Investment Risks

Risk Factors	Impact	Mitigation Strategies
Patent expiration	Revenue decline	Diversify portfolio, develop new formulations
Competition	Market share erosion	Brand loyalty, clinical differentiation
Regulatory shifts	Approval delays	Proactive engagement with authorities

---

4. Comparative Analysis with Similar Products

Parameter	CARDIZEM LA	Amlodipine ER	Verapamil ER
Market Launch Year	1980s	1990s	1980s
Patent Expiry (US)	2014	2010	1998
Therapeutic Window	Hypertension/Angina	Hypertension/Cholesterol	Hypertension/Arrhythmia
Market Share (2022)	~15% (niche)	~25%	~20%
Pricing	Premium pre-expiration	Competitive/Genuine	Competitive

The comparability indicates that long-acting diltiazem formulations are increasingly commoditized, with newer agents gaining ground through better tolerability or expanded indications.

---

5. Strategic Considerations for Stakeholders

Strategy Area	Approaches
Market Penetration	Focus on niche indications, hospital formularies
Product Differentiation	Develop combination therapies, novel delivery systems
Regulatory Actions	Pursue supplemental indications, biosimilar approvals
Partnerships & Licensing	Collaborate with biotech for niche drugs
Cost Optimization	Streamline manufacturing, reduce procurement costs

---

6. Key Drivers and Barriers to Investment

Drivers	Barriers
Large, mature market with established use	Patent cliffs, generic commoditization
Expanding global markets	Regulatory and reimbursement challenges
Modest R&D requirements	Price erosion, market saturation
Potential for niche repositioning	Competitive pressure from newer agents

---

7. Comparative Market Studies & Clinical Trends

• Meta-analyses and clinical trials suggest no significant differential in long-term cardiovascular outcomes among long-acting CCBs, marking price as a critical success factor.
• Exclusivity for novel formulations or combination therapies could provide a high-margin niche market.

---

8. Regulatory and Policy Environment Impact

• US FDA has supported faster approvals for simplified biosimilar and generic pathways.
• EMA maintains strict standards but encourages biosimilar entry.
• Reimbursement policies increasingly favor cost-effective generics, constraining margins for branded drugs.

---

9. Future Outlook and Market Opportunities

Potential Opportunities	Details
Formulation Innovation	Once-daily, fixed-dose combination pills
Indication Expansion	Heart failure, arrhythmias, combination therapies
Emerging Markets	Significant growth in Asia-Pacific, Latin America
Digital and Personalized Medicine	Monitoring devices, genetic profiling

---

10. Summary of Critical Investment Considerations

• Market Saturation & Competition: Generic erosion limits revenue unless differentiated.
• Patent Environment: Patent expirations necessitate diversification.
• Emerging Alternatives: Competing agents and new drug classes affect future demand.
• Strategic Development: Niche markets, formulation enhancements, or indications offer growth paths.
• Cost Management: Essential to sustain margins amidst pricing pressures.

---

Key Takeaways

• Market Maturity: Reached in most developed markets, with significant generic penetration reducing margins.
• Revenue Trajectory: Likely decline post-patent expiry unless product repositioned or reformulated.
• Growth Opportunities: Niche utilization, combination therapies, and emerging markets hold potential.
• Strategic Focus: Innovation and partnerships are crucial to sustain relevance and profitability.
• Risk Management: Continuous monitoring of regulatory, competitive, and clinical shifts vital to investment planning.

---

FAQs

Q1. What is the current patent status of CARDIZEM LA?
A1. The primary patent expired in the US in 2014, leading to widespread generic entry and significant dose of market erosion. No recent patents are active on the extended-release formulation.

Q2. How does CARDIZEM LA compare with newer calcium channel blockers?
A2. While effective historically, newer agents like amlodipine are preferred due to better tolerability profiles, once-daily dosing, and cost advantages, reducing the competitive attractiveness of CARDIZEM LA.

Q3. What are primary growth strategies for generic formulations like CARDIZEM LA?
A3. Strategies include targeting niche indications, developing combination formulations, securing formulary positioning, and expanding into emerging markets with high untreated prevalence.

Q4. How does global regulatory environment affect such drugs?
A4. Stringent guidelines and faster biosimilar pathways influence entry costs and times, requiring strategic regulatory engagement, especially in large markets like the US and EU.

Q5. What emerging therapies could threaten the market share of CARDIZEM LA?
A5. Newer multi-mechanistic agents (including ARNIs, SGLT2 inhibitors), device-based therapies, and personalized medicine may decrease reliance on traditional CCBs over time.

---

References

1. Pfizer Inc. Annual Reports 2000-2014.
2. GlobalData Healthcare. Calcium Channel Blockers Market Forecast 2022–2027.
3. U.S. Food & Drug Administration (FDA). Patent and Exclusivity Data.
4. European Medicines Agency (EMA). Market Authorizations and Policies.
5. ClinicalTrials.gov. Long-term efficacy studies of Diltiazem formulations.